Numaferm
Private Company
Funding information not available
Overview
Numaferm is a Hamburg-based biotech firm operating at the intersection of synthetic biology and biologics production. The company has developed two core technology platforms: Numascreen™ for high-diversity phage display-based lead discovery and Numatech™ for high-titer, cost-effective microbial expression. With an ISO 9001:2015 certified operation and a team of ~30 experts, Numaferm serves as a service provider and partner for pharmaceutical, agricultural, and industrial clients, aiming to democratize access to peptide and protein-based solutions. Its business model combines fee-for-service projects with technology licensing and process development partnerships.
Technology Platform
Numascreen™ (high-diversity phage display libraries for peptides >20aa) and Numatech™ (high-titer microbial expression platform) collectively form the 'Numaswitch' integrated discovery-to-production platform.
Opportunities
Risk Factors
Competitive Landscape
Numaferm competes with large CROs/CMOs offering peptide services, specialized peptide discovery firms, and in-house R&D teams at pharmaceutical and agriscience companies. Its differentiation hinges on the combined offering of high-diversity discovery for long peptides and a proprietary, cost-effective microbial expression system, which it bundles into an integrated service from discovery to production.